Holen Sie sich die Stockscreener-App
58.72
0.51%
0.30
Schlusskurs vom Vortag:
$58.42
Offen:
$58.45
24-Stunden-Volumen:
2.62M
Relative Volume:
0.73
Marktkapitalisierung:
$26.03B
Einnahmen:
$2.44B
Nettoeinkommen (Verlust:
$1.36B
KGV:
30.75
EPS:
1.9093
Netto-Cashflow:
$574.14M
1W Leistung:
+4.28%
1M Leistung:
+9.61%
6M Leistung:
+46.40%
1J Leistung:
+62.66%
1-Tages-Spanne:
$58.10
$58.77
1-Wochen-Bereich:
$56.45
$59.44
52-Wochen-Spanne:
$34.08
$59.44
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
58.72 | 26.03B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
472.57 | 119.94B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
651.18 | 68.27B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.72 | 53.28B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.03 | 38.91B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
266.99 | 35.65B | 4.29B | 577.22M | 641.34M | 4.2086 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | UBS | Neutral → Buy |
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
RPHC6166013 Bond Risk Profile - TradingView
RPHC6166013 Bond Profile — Key Metrics - TradingView
Royalty Pharma acquires royalty stake in AstraZeneca drug By Investing.com - Investing.com South Africa
Royalty Pharma acquires royalty stake in AstraZeneca drug - Investing.com
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune - marketscreener.com
Royalty Pharma deal includes $125M upfront for heart antibody - Stock Titan
Royalty Pharma PLC $RPRX Shares Bought by Swiss National Bank - MarketBeat
Mediolanum International Funds Ltd Sells 40,296 Shares of Royalty Pharma PLC $RPRX - MarketBeat
SEB Asset Management AB Invests $12.97 Million in Royalty Pharma PLC $RPRX - MarketBeat
California Public Employees Retirement System Cuts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Holdings Lowered by AlTi Global Inc. - MarketBeat
How (RPRX) Movements Inform Risk Allocation Models - Stock Traders Daily
Hsbc Holdings PLC Acquires 1,486,020 Shares of Royalty Pharma PLC $RPRX - MarketBeat
RPHC5824521 Bond Profile — Key Metrics - TradingView
Royalty Pharma declares $0.235 dividend - MSN
US78081BAP8 Bond Coupon Profile — Rate & Payments - TradingView
RPHC5237916 Bond Coupon Profile — Rate & Payments - TradingView
RPHC5237916 Bond Profile — Key Metrics - TradingView
RPHC6166012 Bond Risk Profile - TradingView
Royalty Pharma declares $0.235 quarterly dividend By Investing.com - Investing.com South Africa
Royalty Pharma declares $0.235 quarterly dividend - Investing.com UK
Press Release: Royalty Pharma Declares Third Quarter 2026 Dividend - Moomoo
Royalty Pharma Maintains Quarterly Dividend at $0.235 a Share, Payable on Sept. 10 to Shareholders of Record on Aug. 14 - marketscreener.com
Royalty Pharma Announces Third Quarter 2026 Dividend of $0.235 per Class A Ordinary Share - Quiver Quantitative
Royalty Pharma plc (RPRX) Declares $0.235 Quarterly Dividend; 1.6% Yield - StreetInsider
Royalty Pharma dividend arrives Sept. 10 for Aug. 14 record-date holders - Stock Titan
Royalty Pharma stock hits all-time high at 58.85 USD By Investing.com - Investing.com South Africa
RPHC6166012 Bond Coupon Profile — Rate & Payments - TradingView
Royalty Pharma (NASDAQ:RPRX) Sets New 12-Month HighHere's Why - MarketBeat
Royalty Pharma stock hits all-time high at 58.85 USD - Investing.com
Royalty Pharma PLC $RPRX Shares Sold by C WorldWide Group Holding A S - MarketBeat
RPHC5824522 Bond Coupon Profile — Rate & Payments - TradingView
Royalty Pharma to announce Q2 2026 financial results on August 5 - scanx.trade
Royalty Pharma schedules 8 a.m. webcast for Aug. 5 results - Stock Titan
RPHC5222527 Bond Profile — Key Metrics - TradingView
Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026 - Yahoo Finance
US78081BAN3 Bond Coupon Profile — Rate & Payments - TradingView
US78081BAN3 Bond Risk Profile - TradingView
Royalty Pharma PLC $RPRX Shares Sold by J. Safra Sarasin Holding AG - MarketBeat
Calamos Advisors LLC Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
RPHC5824522 Bond Risk Profile - TradingView
US78081BAN3 Bond Profile — Key Metrics - TradingView
RPHC5824522 Bond Profile — Key Metrics - TradingView
Calamos Wealth Management LLC Acquires New Shares in Royalty Pharma PLC $RPRX - MarketBeat
US78081BAQ6 Bond Coupon Profile — Rate & Payments - TradingView
Canal Insurance CO Acquires Shares of 20,000 Royalty Pharma PLC $RPRX - MarketBeat
RPHC5237891 Bond Profile — Key Metrics - TradingView
Royalty Pharma (RPRX) Bernstein Insights: Healthcare Leaders and Disruptors2nd Annual Healthcare Forum summary - Quartr
RPHC5237891 Bond Coupon Profile — Rate & Payments - TradingView
RPHC5237891 Bond Risk Profile - TradingView
US78081BAQ6 Bond Risk Profile - TradingView
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):